However, a recent study published in These findings support structured de-escalation as a promising strategy to reduce treatment burden without sacrificing efficacy, noted the study authors
Here, we review the role of GLP-1 and the actions of associated therapies on glucose metabolism, the gutrenal axis, classical renal risk factors, and renal end points in randomized controlled trials of GLP-1 receptor agonists and DPP-4 inhibitors in patients with T2DM
Higher doses often come at a higher price, so patients on larger doses may see the upper end of this range
doi:10.1186/s12958-018-0391-5 Lim J, Luderer U
Given that GLP-1 receptor agonists are revolutionizing the treatment of obesity, we thought it would be an excellent drug to evaluate for potential protective effects against obesity-related cancers
Track appetite first, then the scale